乳腺浸润性导管癌与癌前病变中错配修复蛋白hMSH2表达的研究  

Study on the Expression of Mismatch Repair Protein hMSH2 in Breast Invasive Ductal Carcinoma and Precancerous Lesions

作　　者：付琼[1] 叶勇斌 吴翔燕[1] 刘娟[1] 杨文君[1] 

机构地区：[1]杭州师范大学附属医院,浙江杭州310015 [2]杭州市余杭区第三人民医院

出　　处：《浙江预防医学》2010年第9期7-10,共4页Zhejiang Journal of Preventive Medicine

摘　　要：目的探讨错配修复基因hMSH2在乳腺浸润性导管癌和癌前病变中的表达及与临床病理指标的关系。方法采用免疫组化EnVision法检测75例乳腺浸润性导管癌、20例癌前病变(导管内乳头状瘤病13例,导管上皮不典型增生7例)及30例正常乳腺组织中hMSH2蛋白的表达情况。结果乳腺浸润性导管癌和癌前病变与正常乳腺组织相比hMSH2蛋白表达阳性率均明显降低,分别为72%和80%(P<0.05)。hMSH2在乳腺癌中的表达率低于癌前病变组,但两者差异无统计学意义(P>0.05)。乳腺癌中hMSH2表达降低与肿瘤体积大、组织分化差和腋窝淋巴结转移有关(P<0.05),与患者年龄、临床分期及C-erbB-2、ER、PR表达无关(P>0.05)。结论错配修复蛋白hMSH2表达缺陷是乳腺癌多步骤发展过程的早期事件,在进展阶段与乳腺癌的低分化和转移关系密切。Objective To investigate the expression and clinicopathologic parameter of the mismatch repair gene hMSH2 in breast invasive ductal carcinoma and precancerous lesions.Methods Immunohistochemical EnVision method was performed to detected hMSH2 protein expression in 75 cases of primary invasive breast carcinomas,20 archival precancerous lesion specimens of the breast and 30 cases of normal breast tissues.Results Positive expression rates of hMSH2 protein in breast carcinoma and precancerous lesion were 72% and 80%,respectively,significantly lower than that in nomal control tissues（P0.05）.Attenuated expression of hMSH2 in breast cancers were much more than in precancerous lesions,whereas there was no statistical difference between those two diseases（P0.05）.Decreased expression of hMSH2 was significantly correlated with tumor size,poor histological differentiation and axillary lymph node metastasis（P0.05）,but not related to age,clinical stage,C-erbB-2 expression,ER and PR status（P0.05）.Conclusion Defective expression of MMR hMSH2 may play a role in the early stage during multistep breast-carcinogenesis,and it indicates poor histologic differentiation and metastasis in breast carcinoma.

关 键 词：乳腺浸润性导管癌 癌前病变 DNA错配修复基因 HMSH2 免疫组织化学 

分 类 号：R339.23[医药卫生—人体生理学]